LBRX
NASDAQ HealthcareLB Pharmaceuticals Inc - Common Stock
Biotechnology
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
๐ Market Data
| Price | $46.23 |
|---|---|
| Volume | 261,752 |
| Market Cap | 1.49B |
| RSI (14-Day) | 73.9 Overbought |
| 200-Day MA | $26.28 |
| 50-Day MA | $34.92 |
| 52-Week High | $49.14 |
| 52-Week Low | $13.36 |
| Forward P/E | -9.34 |
| Price / Book | 3.99 |
๐ฏ Investment Strategy Scores
LBRX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (88/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ช Falling Knife (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find LBRX in your text
Paste any article, transcript, or post โ the tool will extract LBRX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.